Miltenyi Biomedicine GmbH
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Miltenyi Biomedicine GmbH
RECRUITINGPhase 1 / Phase 2NCT06189157
MB-CART19.1 in Refractory SLE
This is a phase l/ll open-label, multicentre, interventional single-arm trial of MB-CART19.1 in patients with refractory SLE systemic lupus erythematosus. In the phase I part, a...
Sponsor: Miltenyi Biomedicine GmbHEnrolling: 293 locations
SLE - Systemic Lupus Erythematosus
RECRUITINGPhase 1 / Phase 2NCT06347718
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
The investigational product is designed to effectively combat B cells in patients with autoimmune diseases. Autologous T cells enriched with CD4/CD8 are genetically engineered...
Sponsor: Miltenyi Biomedicine GmbHEnrolling: 241 location
Systemic Lupus ErythematosusSystemic SclerosisDermatomyositis+1